Literature DB >> 19682317

Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus.

A Boyd1, K Lacombe, P Miailhes, J Gozlan, P Bonnard, J-M Molina, C Lascoux-Combe, L Serfaty, E Gault, M Desvarieux, P-M Girard.   

Abstract

Virological interactions of hepatitis B (HBV), hepatitis C (HCV) and hepatitis D (HDV) viruses in HIV-infected patients have been poorly characterized especially under treatment influences. Undetection rates of hepatitis viruses were longitudinally analyzed in a 3-year cohort of 308 HIV-HBV co-infected patients and compared using Generalized Estimating Equation models adjusted for age, HIV-RNA, CD4 cell-count and antiviral treatment. Chronic hepatitis co-infection in HIV-infected patients (age years, SD) was: 265 HBV (40.7, 8.2); 19 HBV-HCV (39.7, 4.1); 12 HBV-HDV (35.2, 9.9); 12 HBV-HCV-HDV (39.2, 5.2). At inclusion, treatment with lamivudine/tenofovir was not significantly different between co-infection groups. HBV suppression was significantly associated with HDV (aOR = 3.85, 95%CI 1.13-13.10, P = 0.03) and HCV tri-infection (aOR = 2.65, 95%CI 1.03-6.81, P = 0.04), but marginally associated with HIV-HBV-HCV-HDV (aOR = 2.32, 95%CI 0.94-5.74, P = 0.07). In quad-infection, lower HDV-undetectability (vs HIV-HBV-HDV, P = 0.2) and higher HCV-undetectability (vs HIV-HBV-HCV, P = 0.1) were demonstrated. The degree of HBV suppression varied between visits and co-infection groups [range of aOR during follow-up (vs HIV-HBV co-infection): HIV-HBV-HCV = 2.23-5.67, HIV-HBV-HDV = 1.53-15.17]. In treated co-infected patients, HDV expressed continuous suppression over HCV- and HBV-replications. Peaks and rebounds from undetectable hepatitis B, C and/or D viremia warrant closer follow-up in this patient population. HDV-replication was uncontrolled even with antiviral treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19682317     DOI: 10.1111/j.1365-2893.2009.01153.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  9 in total

1.  Low sero-prevalence of hepatitis delta antibodies in HIV/ hepatitis B co-infected patients attending an urban HIV clinic in Uganda.

Authors:  Elizabeth Katwesigye; Emmanuel Seremba; Fred Semitala; Ponsiano Ocama
Journal:  Afr Health Sci       Date:  2016-12       Impact factor: 0.927

2.  Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users.

Authors:  Lauren M Kucirka; Homayoon Farzadegan; Jordan J Feld; Shruti H Mehta; Mark Winters; Jeffrey S Glenn; Gregory D Kirk; Dorry L Segev; Kenrad E Nelson; Morgan Marks; Theo Heller; Elizabeth T Golub
Journal:  J Infect Dis       Date:  2010-09-15       Impact factor: 5.226

Review 3.  Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead.

Authors:  Heiner Wedemeyer; Michael P Manns
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

Review 4.  Therapy of Delta Hepatitis.

Authors:  Cihan Yurdaydin; Ramazan Idilman
Journal:  Cold Spring Harb Perspect Med       Date:  2015-08-07       Impact factor: 6.915

5.  Hepatic decompensation in patients with HIV/Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) triple infection versus HIV/HCV coinfection and the effect of anti-HBV nucleos(t)ide therapy.

Authors:  Vincent Lo Re; Li Wang; Scott Devine; Onur Baser; Temitope Olufade
Journal:  Clin Infect Dis       Date:  2014-06-18       Impact factor: 9.079

6.  Is there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report.

Authors:  Knud Schewe; Christian Noah; Hüseyin Sirma; Stefan Schmiedel; Jan Van Lunzen; Jürgen Kurt Rockstroh; Oliver Schildgen
Journal:  Viruses       Date:  2010-07-29       Impact factor: 5.818

7.  Frequency and Genotype of Hepatitis D Virus Infection in Patients Infected with HIV and Those Undergoing Hemodialysis.

Authors:  Mohammad Reza Aghasadeghi; Minoo Mohraz; Golnaz Bahramali; Arezoo Aghakhani; Mohammad Banifazl; Maryam Foroughi; Farrokhlagha Ahmadi; Ali Eslamifar; Seyed Mehdi Sadat; Amitis Ramezani
Journal:  Hepat Mon       Date:  2013-05-11       Impact factor: 0.660

8.  Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study.

Authors:  Bo Langhoff Hønge; Sanne Jespersen; Candida Medina; David da Silva Té; Zacarias José da Silva; Sharon Lewin; Lars Østergaard; Christian Erikstrup; Christian Wejse; Alex Lund Laursen; Henrik Krarup
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

9.  Low sero-prevalence of hepatitis delta antibodies in HIV/ hepatitis B co-infected patients attending an urban HIV clinic in Uganda.

Authors:  Elizabeth Katwesigye; Emmanuel Seremba; Fred Semitala; Ponsiano Ocama
Journal:  Afr Health Sci       Date:  2017-12       Impact factor: 0.927

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.